TOP2A and breast cancer: Despite that molecular testing of TOP2A and the in situ analysis of tumor landscape after neoadjuvant chemotherapy are promising readouts useful to predict tumor response and survival in treated BC patients [3, 30], the usefulness of functional analyses of peripheral blood leukocytes to predict tumor responsiveness to chemotherapy remains unknown.